### List of Figures

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Figure 1</td>
<td>Circular diagram of HPV-16 genome and open reading frames</td>
<td>3</td>
</tr>
<tr>
<td>Figure 2</td>
<td>The course of events that, over time, can lead to the development of precancerous and cancerous cervical tumors</td>
<td>4</td>
</tr>
<tr>
<td>Figure 3</td>
<td>Processes involved in HPV-induced carcinogenesis</td>
<td>7</td>
</tr>
<tr>
<td>Figure 4</td>
<td>Stimulation of cell-cycle progression by high-risk HPV types</td>
<td>8</td>
</tr>
<tr>
<td>Figure 5</td>
<td>Bioconversion pathway of Garlic Organosulfur Compounds</td>
<td>17</td>
</tr>
<tr>
<td>Figure 6</td>
<td>Chemical reactions in processed <em>Allium</em> vegetables and generation of organosulfur compounds</td>
<td>18</td>
</tr>
<tr>
<td>Figure 7</td>
<td>Chemical structures of widely studied natural organosulfur compounds</td>
<td>19</td>
</tr>
<tr>
<td>Figure 8</td>
<td>Schematic representation of the intrinsic and extrinsic apoptotic pathways</td>
<td>32</td>
</tr>
<tr>
<td>Figure 9</td>
<td>Schematic representation of mitochondrial membrane permeabilization</td>
<td>33</td>
</tr>
<tr>
<td>Figure 10</td>
<td>Glutathione biochemistry and intracellular pools</td>
<td>41</td>
</tr>
<tr>
<td>Figure 11</td>
<td>Dose dependent inhibition of growth of cervical cancer HeLa cells treated with Allicin for 24 hour assessed by MTT assay</td>
<td>58</td>
</tr>
<tr>
<td>Figure 12</td>
<td>Dose dependent inhibition of growth of cervical cancer HeLa cells treated with Allicin for 48 hour assessed by MTT assay</td>
<td>59</td>
</tr>
<tr>
<td>Figure 13</td>
<td>Dose dependent inhibition of growth of cervical cancer HeLa cells treated with Allicin for 24 hour assessed by Trypan Blue dye exclusion assay</td>
<td>60</td>
</tr>
<tr>
<td>Figure 14</td>
<td>Dose dependent inhibition of growth of cervical cancer HeLa cells treated with Allicin for 48 hour assessed by Trypan Blue dye exclusion assay</td>
<td>61</td>
</tr>
<tr>
<td>Figure 15</td>
<td>Cell cycle analysis of Allicin-treated HeLa cells</td>
<td>63</td>
</tr>
<tr>
<td>Figure 16</td>
<td>Cell cycle analysis of Allicin (1.5 μM)-treated HeLa cells</td>
<td>64</td>
</tr>
<tr>
<td>Figure 17</td>
<td>Cell cycle analysis of Allicin (3 μM)-treated HeLa cells</td>
<td>65</td>
</tr>
</tbody>
</table>
Figure 18  FITC-Annexin V assay for measurement of apoptosis in Allicin-treated HeLa cells

Figure 19  Amount of Apoptosis in Allicin-treated HeLa cells

Figure 20  Modulation of Bax and Bcl-2 levels in Allicin-treated HeLa cells

Figure 21  Mitochondrial release of cytochrome c by Allicin-treated HeLa cells

Figure 22  Dose and time dependent activation of caspase-9 in Allicin-treated HeLa cells

Figure 23  Dose and time dependent activation of caspase-3 in Allicin-treated HeLa cells

Figure 24  Cleavage and activation of caspase-9 in Allicin-treated HeLa cells

Figure 25  Cleavage and activation of caspase-3 in Allicin-treated HeLa cells

Figure 26  Suppression of Allicin-induced caspase-9 activation by caspase-9 inhibitor (Z-LEHD-FMK)

Figure 27  Abrogation of Allicin-induced growth suppression of HeLa cells by caspase-9 inhibitor (Z-LEHD-FMK)

Figure 28  Suppression of Allicin-induced caspase-3 activation by caspase-3 inhibitor (Z-DEVD-FMK)

Figure 29  Abrogation of Allicin-induced growth suppression of HeLa cells by caspase-3 inhibitor (Z-DEVD-FMK)

Figure 30  Abrogation of Allicin-induced growth suppression of HeLa cells by general caspase inhibitor (Z-VAD-FMK)

Figure 31  PARP Cleavage in Allicin-treated HeLa cells

Figure 32  Effect of pretreatment of Cyclosporin A (CsA, 5 μM) on cell viability of Allicin (1.5 μM)-treated HeLa cells

Figure 33  Effect of pretreatment of Cyclosporin A (CsA, 5 μM) on cell viability of Allicin (3.0 μM)-treated HeLa cells

Figure 34  Effect of Cyclosporin A (CsA, 5 μM) on Allicin (3.0 μM)-Induced Apoptosis in HeLa cells
Figure 35  Effect of Cyclosporin A (CsA, 5 μM) on cell cycle distribution of Allicin (3.0 μM)-treated HeLa cells

Figure 36  Effect of Allicin (1.5 μM) on Glutathione (GSH) content of HeLa cells

Figure 37  Effect of Allicin (3.0 μM) on Glutathione (GSH) content of HeLa cells

Figure 38  Minimal Glutathione (GSH) level in Allicin-treated HeLa cells

Figure 39  Effect of Allicin (3.0 μM) on free Thiol (-SH) content of cytosolic fraction of HeLa cells

Figure 40  Effect of Allicin (3.0 μM) on free Thiol (-SH) content of mitochondrial fraction of HeLa cells

Figure 41  Time dependent decrease of Glutathione (GSH) level in Allicin (1.5 μM)-treated HeLa cells pretreated with Buthionine sulfoximine (BSO)

Figure 42  Time dependent decrease of Glutathione (GSH) level in Allicin (3.0 μM)-treated HeLa cells pretreated with Buthionine sulfoximine (BSO)

Figure 43  Effect of pretreatment of Buthionine sulfoximine (BSO) on cell viability of Allicin (1.5 μM)-treated HeLa cells

Figure 44  Effect of pretreatment of Buthionine sulfoximine (BSO) on cell viability of Allicin (3.0 μM)-treated HeLa cells

Figure 45  Effect of N-acetyl cysteine (NAC, 0.1 mM) on cell viability of Allicin-treated HeLa cells

Figure 46  Effect of N-acetyl cysteine (NAC, 0.5 mM) on cell viability of Allicin-treated HeLa cells

Figure 47  Effect of N-acetyl cysteine (NAC, 1 mM) on cell viability of Allicin-treated HeLa cells

Figure 48  Effect of N-acetyl cysteine (NAC, 1 mM) on cell cycle distribution of Allicin (3.0 μM)-treated HeLa cells

Figure 49  Effect of N-acetyl cysteine (NAC, 1 mM) on Allicin (3.0 μM)-Induced apoptosis in HeLa cells
Figure 50  Downregulation of HPV E6 and E7 oncoprotein in Allicin-treated HeLa cells

Figure 51  Upregulation of p53 tumor suppressor protein in Allicin-treated HeLa cells

Figure 52  Dose dependent reduction in viability of monocytes, isolated from blood of cervical cancer patients, treated with Allicin for 24 hour assessed by MTT assay

Figure 53  Dose dependent reduction in viability of monocytes, isolated from blood of cervical cancer patients, treated with Allicin for 48 hour assessed by MTT assay

Figure 54  Dose and time dependent activation of caspase-9 in Allicin-treated monocytes

Figure 55  Dose and time dependent activation of caspase-3 in Allicin-treated monocytes

Figure 56  Abrogation of Allicin-induced reduction in viability of monocytes by general caspase inhibitor (Z-VAD-FMK)

Figure 57  Effect on TNF-α expression in monocytes treated with Allicin for 24 hour

Figure 58  Effect on TNF-α expression in monocytes treated with Allicin for 48 hour

Figure 59  Effect on IL-1α expression in monocytes treated with Allicin for 24 hour

Figure 60  Effect on IL-1α expression in monocytes treated with Allicin for 48 hour

Figure 61  Effect on IL-6 expression in monocytes treated with Allicin for 24 hour

Figure 62  Effect on IL-6 expression in monocytes treated with Allicin for 48 hour